Paper Details

  1. Home
  2. Paper Details

Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines <i>Versus</i> Surgery-alone for Gastric Cancer.

Author: DokiYuichiro, FujitaJunya, FujitaniKazumasa, FujiwaraYoshiyuki, HiraoMotohiro, ImamuraHiroshi, KimuraYutaka, MoonJeong Ho, MoriMasaki, TakiguchiShuji, TamuraShigeyuki, YanoMasahiko

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. The overall survival rate did not significantly differ between the two groups. However, patients with stage II disease and those receiving uracil-tegafur treatment in the adjuvant group showed significantly better prognosis than those in the surgery-alone group.
Paper Details　
Original Abstract of the Article :
AIM: This prospective randomized study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. PATIENTS AND METHODS: Patients with pathological stage IB-IIIA disease were randomly assigned to the following groups: ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.21873/anticanres.11661

データ提供：米国国立医学図書館（NLM）

Adjuvant Chemotherapy for Gastric Cancer: A Battle Against a Silent Enemy

Gastric cancer is a serious disease, like a hidden enemy lurking in the desert. This study explores the effectiveness of adjuvant chemotherapy with fluoropyrimidines for treating stage IB-IIIA gastric cancer. The researchers conducted a randomized controlled trial comparing surgery alone to surgery followed by adjuvant chemotherapy. They found that adjuvant chemotherapy did not significantly improve overall survival, but it may be beneficial for patients with stage II disease.

Combating Gastric Cancer: A Multifaceted Approach

The study suggests that surgery alone is often sufficient for treating stage IB-IIIA gastric cancer, but adjuvant chemotherapy may be beneficial for specific subgroups of patients. It's like fighting a hidden enemy in the desert, where a multifaceted approach is often necessary. The researchers found that adjuvant chemotherapy with uracil-tegafur showed promising results for patients with stage II disease.

Hope for Patients With Stage II Disease

This research offers hope for patients with stage II gastric cancer, like finding a hidden oasis in the desert. The study found that adjuvant chemotherapy with uracil-tegafur may improve survival for this subgroup of patients. This is encouraging news and suggests that further research is needed to explore the potential benefits of adjuvant chemotherapy for specific stages of gastric cancer.

Dr.Camel's Conclusion

The effectiveness of adjuvant chemotherapy for gastric cancer is a complex issue, like navigating a treacherous desert. This study highlights the potential benefits of adjuvant chemotherapy for specific stages of gastric cancer, offering hope for those facing this silent enemy. Further research is needed to explore the optimal use of adjuvant chemotherapy in the fight against this disease.

Date :
  1. Date Completed 2017-08-18
  2. Date Revised 2017-08-18
Further Info :

Pubmed ID

28551645

DOI: Digital Object Identifier

10.21873/anticanres.11661

Related Literature

Article Analysis
・Effects of floxuridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.